Systemic delivery of agents across the blood-brain barrier
Getting genes, drugs or devices from the bloodstream into brain cells at useful dose, brain-wide, after a simple injection.
State of the art
BI-hTFR1 capsid crosses human brain endothelium in vitro and transduces CNS of human-TFRC knock-in mice ~40-50x better than AAV9 (Science 2024); focused-ultrasound BBB opening used clinically in small trials.
- Receptor targeting is species-specific; capsids binding human TfR1 often fail in macaque
- Pre-existing anti-AAV immunity excludes a large fraction of patients and blocks redosing
- Dose needed for brain-wide coverage drives liver toxicity and manufacturing cost
Who’s working on it
- Benjamin DevermanResearcherStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard
Engineered BI-hTFR1, an AAV9 capsid reprogrammed to bind human transferrin receptor, giving 40-50x more CNS expression than AAV9 in human TFRC knock-in mice (Science, 2024)
- Denali Therapeutics ↗Company
Its TransportVehicle platform produced AVLAYAH (tividenofusp alfa), approved by the FDA in March 2026 as the first biologic specifically designed to cross the blood-brain barrier
- Voyager Therapeutics ↗Company
Used its TRACER platform to find cross-species BBB-penetrant capsids and identified ALPL as the receptor they use; VCAP-102 gave 20-400x more brain gene transfer than AAV9 in primates (2025)
- Sangamo TherapeuticsCompany
Reported its STAC-BBB capsid achieving widespread brain transduction after intravenous dosing in non-human primates at clinically relevant doses (2024)
- Hong ChenResearcherWashington University in St. Louis
Develops focused-ultrasound BBB opening, sonobiopsy and intranasal FUS delivery, the leading physical alternative to engineered carriers, now in small clinical studies
Philanthropic funder that has underwritten most early clinical trials of focused-ultrasound BBB opening for brain tumours and neurodegeneration
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| research | Directed-evolution and design campaigns for capsids and shuttle peptides validated in nonhuman primates, not just humanized mice | $$$ $100M – $1B |
| engineering | Manufacturing capacity for 1e16-plus vector genome doses at clinical purity | $$$ $100M – $1B |